Ginger Nicol

Dr. Ginger Nicol

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2017 in European Eating Disorders Review
Verified
Journal Article
Closed access
PDF file
ADAlexis E. Duncan
Alexis E. Duncan
HZHannah N. Ziobrowski
Hannah N. Ziobrowski
GNGinger Nicol
Ginger Nicol

22 November 2022 in JMIR Formative Research
Verified
Journal Article
Open access
GNGinger Nicol
Ginger Nicol
RWRuoyun Wang
Ruoyun Wang
SGSharon Graham
Sharon Graham
SDSherry Dodd
Sherry Dodd
JGJane Garbutt
Jane Garbutt
Background: Symptoms of depression and anxiety, suicidal ideation, and self-harm have escalated among adolescents to crisis levels during the COVID-19 pandemic. As a result, primary care providers (PCPs) are often called on to provide first-line care for these youth. Digital health interventions can extend mental health specialty care, but few are evidence based. We evaluated the feasibility of delivering an evidence-based mobile health (mHealth) app with an embedded conversational agent to deliver cognitive behavioral therapy (CBT) to symptomatic adolescents presenting in primary care settings during the pandemic. Objective: In this 12-week pilot study, we evaluated the feasibility of delivering the app-based intervention to adolescents aged 13 to 17 years with moderate depressive symptoms who were treated in a practice-based research network (PBRN) of academically affiliated primary care clinics. We also obtained preliminary estimates of app acceptability, effectiveness, and usability. Methods: This small, pilot randomized controlled trial (RCT) evaluated depressive symptom severity in adolescents randomized to the app or to a wait list control condition. The primary end point was depression severity at 4-weeks, measured by the 9-item Patient Health Questionnaire (PHQ-9). Data on acceptability, feasibility, and usability were collected from adolescents and their parent or legal guardian. Qualitative interviews were conducted with 13 PCPs from 11 PBRN clinics to identify facilitators and barriers to incorporating mental health apps in treatment planning for adolescents with depression and anxiety. Results: The pilot randomized 18 participants to the app (n=10, 56%) or to a wait list control condition (n=8, 44%); 17 participants were included in the analysis, and 1 became ineligible upon chart review due to lack of eligibility based on documented diagnosis. The overall sample was predominantly female (15/17, 88%), White (15/17, 88%), and privately insured (15/17, 88%). Mean PHQ-9 scores at 4 weeks decreased by 3.3 points in the active treatment group (representing a shift in mean depression score from moderate to mild symptom severity categories) and 2 points in the wait list control group (no shift in symptom severity category). Teen- and parent-reported usability, feasibility, and acceptability of the app was high. PCPs reported preference for introducing mHealth interventions like the one in this study early in the course of care for individuals presenting with mild or moderate symptoms. Conclusions: In this small study, we demonstrated the feasibility, acceptability, usability, and safety of using a CBT-based chatbot for adolescents presenting with moderate depressive symptoms in a network of PBRN-based primary care clinics. This pilot study could not establish effectiveness, but our results suggest that further study in a larger pediatric population is warranted. Future study inclusive of rural, socioeconomically disadvantaged, and underrepresented communities is needed to establish generalizability of effectiveness and identify implementation-related adaptations needed to promote broader uptake in pediatric primary care. Trial Registration: ClinicalTrials.gov NCT04603053; https://clinicaltrials.gov/ct2/show/NCT04603053

1 April 2010 in Archives of Pediatrics & Adolescent Medicine
Verified
Journal Article
Closed access
PDF file
EMElaine H. Morrato
Elaine H. Morrato
GNGinger Nicol
Ginger Nicol
DMDavid Maahs
David Maahs
BDBenjamin G. Druss
Benjamin G. Druss
DHDaniel M. Hartung
Daniel M. Hartung
JNJohn W. Newcomer
John W. Newcomer
Research from JAMA Pediatrics — Metabolic Screening in Children Receiving Antipsychotic Drug Treatment

3 April 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
GNGinger Nicol
Ginger Nicol
JPJay F. Piccirillo
Jay F. Piccirillo
BMBenoit H. Mulsant
Benoit H. Mulsant
ELEric J. Lenze
Eric J. Lenze

1 May 2016 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
LSLawrence Scahill
Lawrence Scahill
SJSangchoon Jeon
Sangchoon Jeon
SBSusan J. Boorin
Susan J. Boorin
CMChristopher J. McDougle
Christopher J. McDougle
MAMichael G. Aman
Michael G. Aman
BVBenedetto Vitiello
Benedetto Vitiello

1 August 2018 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
GNGinger Nicol
Ginger Nicol
MYMichael D. Yingling
Michael D. Yingling
KFKaren S. Flavin
Karen S. Flavin
JSJulia A. Schweiger
Julia A. Schweiger
BPBruce W. Patterson
Bruce W. Patterson
JNJohn W. Newcomer
John W. Newcomer
Importance Antipsychotic medications are commonly used to treat nonpsychotic disruptive behavioral disorders in youths. Objective To characterize the metabolic effects of first exposure to antipsychotics in youths using criterion standard assessments of body composition and insulin sensitivity. Design, Setting, and Participants This randomized clinical trial recruited antipsychotic-naive youths aged 6 to 18 years in the St Louis, Missouri, metropolitan area who were diagnosed with 1 or more psychiatric disorders and clinically significant aggression and in whom antipsychotic treatment was considered. Participants were enrolled from June 12, 2006, through November 10, 2010. Enrolled participants were randomized (1:1:1) to 1 of 3 antipsychotics commonly used in children with disruptive behavioral disorders and evaluated for 12 weeks. Data were analyzed from January 17, 2011, through August 9, 2017. Interventions Twelve weeks of treatment with oral aripiprazole (n = 49), olanzapine (n = 46), or risperidone (n = 49). Main Outcomes and Measures Primary outcomes included percentage total body fat measured by dual-energy x-ray absorptiometry (DXA) and insulin sensitivity in muscle measured via hyperinsulinemic clamps with stable isotopically labeled tracers. Secondary outcomes included abdominal adiposity measured by magnetic resonance imaging (MRI) and adipose and hepatic tissue insulin sensitivity measured via clamps with tracers. Results The intention-to-treat sample included 144 participants (98 males [68.1%]; mean [SD] age, 11.3 [2.8] years); 74 (51.4%) were African American, and 43 (29.9%) were overweight or obese at baseline. For the primary outcomes, from baseline to week 12, DXA percentage total body fat increased by 1.18% for risperidone, 4.12% for olanzapine, and 1.66% for aripiprazole and was significantly greater for olanzapine than risperidone or aripiprazole (time by treatment interactionP < .001). From baseline to week 12, insulin-stimulated change in glucose rate of disappearance increased by 2.30% for risperidone and decreased by 29.34% for olanzapine and 30.26% for aripiprazole, with no significant difference across medications (time by treatment interaction,P < .07). This primary measure of insulin sensitivity decreased significantly during 12 weeks in the pooled study sample (effect of time,F = 17.38;P < .001). For the secondary outcomes from baseline to week 12, MRI measured abdominal fat increased, with subcutaneous fat increase significantly greater for olanzapine than risperdone or aripiprazole (time by treatment,P = .003). Behavioral improvements occurred with all treatments. Conclusions and Relevance Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine. Such changes, likely attributable to treatment, may be associated with risk for premature cardiometabolic morbidity and mortality. The results inform risk-benefit considerations for antipsychotic use in youths. Trial Registration ClinicalTrials.gov identifier:NCT00205699